Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
11.16
+0.22 (2.01%)
At close: Aug 1, 2025, 4:00 PM
10.90
-0.26 (-2.33%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.

Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.

The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich LifeSciences, Inc.
Greenwich LifeSciences logo
CountryUnited States
Founded2006
IPO DateSep 25, 2020
IndustryBiotechnology
SectorHealthcare
Employees8
CEOSnehal Patel

Contact Details

Address:
Building 14, 3992 Bluebonnet Dr.
Stafford, Texas 77477
United States
Phone832-819-3232
Websitegreenwichlifesciences.com

Stock Details

Ticker SymbolGLSI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$5.75
CIK Code0001799788
CUSIP Number396879108
ISIN NumberUS3968791083
Employer ID20-5473709
SIC Code2834

Key Executives

NamePosition
Snehal S. PatelChief Executive Officer, Chief Financial Officer and Director
Eric RotheFounder and Independent Director
Dr. Frank Joseph Daugherty M.D.Chief Medical Officer and Director
Dr. Jaye L. Thompson Ph.D.Vice President Clinical and Regulatory Affairs
Dr. Christine T. Fischette Ph.D.Vice President of Business Development

Latest SEC Filings

DateTypeTitle
Jul 24, 20258-KCurrent Report
May 20, 202510-QQuarterly Report
May 15, 2025NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Apr 15, 202510-KAnnual Report
Mar 31, 2025NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Dec 20, 2024S-8Securities to be offered to employees in employee benefit plans
Dec 19, 20248-KCurrent Report
Nov 14, 202410-QQuarterly Report
Nov 1, 2024DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 1, 2024ARSFiling